PTX 1.25% 4.1¢ prescient therapeutics limited

Ann: March 2024 Quarterly Update and Appendix 4C, page-19

  1. 248 Posts.
    lightbulb Created with Sketch. 81
    My understanding of the FDA's stance is that the approval of the Registration study will hinge on the outcomes and data from the Phase 2 study. SYC has indicated that results from the study will be consistently disclosed, and that extensive preparations, including the manufacturing processes required for Registration approval, have been undertaken.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.1¢
Change
0.001(1.25%)
Mkt cap ! $32.61M
Open High Low Value Volume
4.0¢ 4.1¢ 4.0¢ $34.57K 860.2K

Buyers (Bids)

No. Vol. Price($)
2 99935 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.1¢ 458172 3
View Market Depth
Last trade - 15.57pm 21/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.